Page last updated: 2024-10-19

niacinamide and Cholera Infantum

niacinamide has been researched along with Cholera Infantum in 17 studies

nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.

Research Excerpts

ExcerptRelevanceReference
"Sorafenib, a tyrosine kinase inhibitor, is approved for the treatment of patients with unresectable hepatocellular carcinoma (HCC) and advanced renal cell carcinoma (RCC)."3.80Management of sorafenib-related adverse events: a clinician's perspective. ( Brose, MS; Frenette, CT; Keefe, SM; Stein, SM, 2014)
"Sorafenib, a tyrosine kinase inhibitor, is indicated for the treatment of patients with unresectable hepatocellular carcinoma (HCC) and advanced renal cell carcinoma (RCC)."3.80Management of common adverse events in patients treated with sorafenib: nurse and pharmacist perspective. ( Grande, C; Walko, CM, 2014)
" This study investigated the safety, pharmacokinetics, and preliminary efficacy of sorafenib in combination with gemcitabine and cisplatin."2.77Phase IB study of sorafenib in combination with gemcitabine and cisplatin in patients with refractory solid tumors. ( Brendel, E; Kornacker, M; Kummer, G; Schultheis, B; Strumberg, D; Xia, C; Zeth, M, 2012)
"Diarrhea was the most common GI event."2.50Risk of gastrointestinal events with sorafenib, sunitinib and pazopanib in patients with solid tumors: a systematic review and meta-analysis of clinical trials. ( Berardi, R; Burattini, L; Cascinu, S; Conti, A; De Giorgi, U; Iacovelli, R; Muzzonigro, G; Pantano, F; Santini, D; Santoni, M, 2014)
" With expanded clinical experience with this class of agents has come the increasing recognition of the diverse adverse effects related to disturbance of VEGF-dependent physiological functions and homeostasis in the cardiovascular and renal systems, as well as wound healing and tissue repair."2.45Adverse effects of anticancer agents that target the VEGF pathway. ( Chen, HX; Cleck, JN, 2009)

Research

Studies (17)

TimeframeStudies, this research(%)All Research%
pre-19906 (35.29)18.7374
1990's0 (0.00)18.2507
2000's2 (11.76)29.6817
2010's8 (47.06)24.3611
2020's1 (5.88)2.80

Authors

AuthorsStudies
Fu, G1
Chen, S1
Liang, L1
Li, X1
Tang, P1
Rao, X1
Pan, M1
Xu, X1
Li, Y1
Yao, Y1
Zhou, Y1
Gao, J2
Mo, S1
Cai, S1
Peng, J1
Zhang, Z1
Clevers, H1
Hua, G1
Lalani, AA1
McKay, RR1
Lin, X1
Simantov, R1
Kaymakcalan, MD1
Choueiri, TK1
Santoni, M1
Conti, A1
De Giorgi, U1
Iacovelli, R1
Pantano, F1
Burattini, L1
Muzzonigro, G1
Berardi, R1
Santini, D1
Cascinu, S1
Brose, MS1
Frenette, CT1
Keefe, SM1
Stein, SM1
Walko, CM1
Grande, C1
Chen, HX1
Cleck, JN1
Reig, M1
Matilla, A1
Bustamante, J1
Castells, L1
de La Mata, M1
Delgado, M1
Moreno, JM1
Forner, A1
Varela, M1
Sorà, F1
Chiusolo, P1
Metafuni, E1
Bellesi, S1
Giammarco, S1
Laurenti, L1
Ausoni, G1
Zini, G1
Bayer, AJ1
Mario, B1
Leone, G1
Sica, S1
Spigel, DR1
Burris, HA1
Greco, FA1
Shipley, DL1
Friedman, EK1
Waterhouse, DM1
Whorf, RC1
Mitchell, RB1
Daniel, DB1
Zangmeister, J1
Bass, JD1
Hainsworth, JD1
Schultheis, B1
Kummer, G1
Zeth, M1
Brendel, E1
Xia, C1
Kornacker, M1
Strumberg, D1
FEINBLATT, TM1
FEINBLATT, HM1
FERGUSON, EA1
BARBIERI, LL1
FELIX, H1
Staehler, M1
Haseke, N1
Schöppler, G1
Stadler, T1
Heinemann, G1
Stief, CG1
Newbold, HL1
Mosher, LR1
Pietranera, P1
Rollier, R1
Rollier, M1

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Tarceva With or Without Apatinib in the First-line Therapy of Advanced Lung Adenocarcinoma With Mutant EGFR:a Phase II Study.[NCT02704767]Phase 260 participants (Anticipated)Interventional2016-06-30Not yet recruiting
A Randomized Double-Blind Placebo-Controlled Phase II Trial of Sorafenib and Erlotinib or Erlotinib Alone in Previously Treated Advanced Non-Small Cell Lung Cancer[NCT00600015]Phase 2166 participants (Actual)Interventional2008-02-29Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

6-month PFS

Progression free survival is defined as the time from the first day of treatment until the day tumor progression was documented. Response was evaluated using the Response Evaluation Criteria in Solid Tumors (RECIST). Progressive Disease (PD): Appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions (1). Percentage of participants who were progression free at 6 month from the start of treatment is reported here. (NCT00600015)
Timeframe: 6 months

Interventionpercentage of participants (Number)
Combination Therapy29
Placebo22

Disease Control Rate (DCR)

"Disease Control Rate (DCR) is defined as the percentage of patients who have a partial/complete/stable response to therapy. Responses were assessed by the Response Evaluation Criteria in Solid Tumors (RECIST; version 1.0).~Complete Response: Disappearance of all target lesions, and disappearance of all non-target lesions.~Partial Response: At least a 30% decrease in the sum of the longest diameter of target lesions (taking as reference the baseline sum of longest diameters) Stable Response: Neither sufficient shrinkage to qualify for partial response, nor sufficient increase to qualify for progressive disease (taking as reference the smallest sum of diameters since the treatment started)." (NCT00600015)
Timeframe: 18 months

Interventionpercentage of participants (Number)
Combination Therapy54
Placebo38

Duration of Response

Duration of response is defined as the time from when objective response is realized until time to first documented disease progression. Disease progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. Objective Response = CR + PR. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI or CT: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions. (NCT00600015)
Timeframe: 18 months

Interventionmonths (Mean)
Combination Therapy4.6430
Placebo5.2234

Overall Objective Response Rate (ORR)

"Overall response rate (ORR) is defined as the percentage of patients who have a partial or complete response to therapy. Responses were assessed by the Response Evaluation Criteria in Solid Tumors (RECIST; version 1.0).~Complete Response: Disappearance of all target lesions, and disappearance of all non-target lesions.~Partial Response: At least a 30% decrease in the sum of the longest diameter of target lesions (taking as reference the baseline sum of longest diameters)" (NCT00600015)
Timeframe: 18 months

Interventionpercentage of participants (Number)
Combination Therapy8.1
Placebo10.9

Overall Survival (OS)

OS is defined as the time from the first treatment until date of death due to any cause. In the absence of confirmation of death or lack of data beyond follow-up period, the survival time was censored to last date the participant was known to be alive. (NCT00600015)
Timeframe: 18 months

InterventionMonths (Median)
Combination Therapy7.62
Placebo7.23

Progression Free Survival (PFS)

"Progression-free survival is defined as the time from the first day of treatment until the day tumor progression was documented. Response was evaluated using the Response Evaluation Criteria in Solid Tumors (RECIST).~Progressive Disease (PD): Appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions" (NCT00600015)
Timeframe: 18 months

InterventionMonths (Median)
Combination Therapy3.38
Placebo1.94

Reviews

3 reviews available for niacinamide and Cholera Infantum

ArticleYear
Risk of gastrointestinal events with sorafenib, sunitinib and pazopanib in patients with solid tumors: a systematic review and meta-analysis of clinical trials.
    International journal of cancer, 2014, Aug-15, Volume: 135, Issue:4

    Topics: Adverse Drug Reaction Reporting Systems; Carcinoma, Renal Cell; Clinical Trials as Topic; Diarrhea;

2014
Adverse effects of anticancer agents that target the VEGF pathway.
    Nature reviews. Clinical oncology, 2009, Volume: 6, Issue:8

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic A

2009
[Managing the side effects of angiogenetic inhibitors in metastatic renal cell carcinoma].
    Der Urologe. Ausg. A, 2006, Volume: 45, Issue:10

    Topics: Adult; Angiogenesis Inhibitors; Benzenesulfonates; Carcinoma, Renal Cell; Drug Eruptions; Female; Ga

2006

Trials

2 trials available for niacinamide and Cholera Infantum

ArticleYear
Randomized, double-blind, placebo-controlled, phase II trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non-small-cell lung cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, Jun-20, Volume: 29, Issue:18

    Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclo

2011
Randomized, double-blind, placebo-controlled, phase II trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non-small-cell lung cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, Jun-20, Volume: 29, Issue:18

    Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclo

2011
Randomized, double-blind, placebo-controlled, phase II trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non-small-cell lung cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, Jun-20, Volume: 29, Issue:18

    Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclo

2011
Randomized, double-blind, placebo-controlled, phase II trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non-small-cell lung cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, Jun-20, Volume: 29, Issue:18

    Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclo

2011
Phase IB study of sorafenib in combination with gemcitabine and cisplatin in patients with refractory solid tumors.
    Cancer chemotherapy and pharmacology, 2012, Volume: 69, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Benzenesulfonates; Ci

2012

Other Studies

12 other studies available for niacinamide and Cholera Infantum

ArticleYear
SIRT1 inhibitors mitigate radiation-induced GI syndrome by enhancing intestinal-stem-cell survival.
    Cancer letters, 2021, 03-31, Volume: 501

    Topics: Acetylation; Animals; Cell Survival; Gastrointestinal Diseases; Histone Deacetylase Inhibitors; Huma

2021
Proton Pump Inhibitors and Survival Outcomes in Patients With Metastatic Renal Cell Carcinoma.
    Clinical genitourinary cancer, 2017, Volume: 15, Issue:6

    Topics: Aged; Axitinib; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Clinical Trials, Phase II

2017
Management of sorafenib-related adverse events: a clinician's perspective.
    Seminars in oncology, 2014, Volume: 41 Suppl 2

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Disease Management; Fatigue

2014
Management of common adverse events in patients treated with sorafenib: nurse and pharmacist perspective.
    Seminars in oncology, 2014, Volume: 41 Suppl 2

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Disease Management; Fatigue

2014
[Recommendations for the management of Sorafenib in patients with hepatocellular carcinoma].
    Gastroenterologia y hepatologia, 2010, Volume: 33, Issue:10

    Topics: Administration, Oral; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cardiovas

2010
Sorafenib for refractory FMS-like tyrosine kinase receptor-3 (FLT3/ITD+) acute myeloid leukemia after allogenic stem cell transplantation.
    Leukemia research, 2011, Volume: 35, Issue:3

    Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase

2011
Treatment of arteriosclerosis and vague abdominal distress with niacinamide hydroiodide, without side-effects.
    The American journal of digestive diseases, 1955, Volume: 22, Issue:1

    Topics: Arteriosclerosis; Gastrointestinal Diseases; Niacin; Niacinamide; Nicotinic Acids

1955
[Effect of nicotinamide overload on riboflavinuria in subjects without liver lesions and in liver disease patients].
    Archivio per le scienze mediche, 1954, Volume: 98, Issue:4

    Topics: Body Fluids; Gastrointestinal Diseases; Humans; Liver Diseases; Niacin; Niacinamide; Nicotinic Acids

1954
[Deficiency in vitamin PP and colopathies].
    La Semaine des hopitaux: therapeutique, 1962, Volume: 38

    Topics: Colon; Colonic Diseases; Disease; Gastrointestinal Diseases; Niacin; Niacinamide; Pellagra

1962
Niacin and the schizophrenic patient.
    The American journal of psychiatry, 1970, Volume: 127, Issue:4

    Topics: Diazepam; Edema; Gastrointestinal Diseases; Humans; Liver Function Tests; Mental Disorders; Niacinam

1970
[Therapeutic value of an association of phospholipids and adrenal cortex in hepatology].
    La Clinica terapeutica, 1971, Mar-31, Volume: 56, Issue:6

    Topics: Adolescent; Adrenal Cortex Hormones; Adrenal Glands; Adult; Aged; Asthenia; Biliary Tract Diseases;

1971
[Treatment of lepromatous leprosy by ethionamide].
    Maroc medical, 1972, Volume: 52, Issue:555

    Topics: Adolescent; Adult; Age Factors; Aged; Avitaminosis; Child; Ethionamide; Female; Gastrointestinal Dis

1972